Abstract
Type 2 diabetes mellitus and microalbuminuria are important risk factors for cardiovascular disease (CVD). Whether these two complications are important and independent risk factors for future CVD events in a high-risk population with clinically manifest vascular disease is unknown. The objectives of this study were to examine the impact of Type 2 diabetes and microalbuminuria on future CVD events. Patients with clinically manifest vascular disease (coronary, cerebral and peripheral vascular disease) from the Second Manifestation of Arterial disease study were followed up for 4 years. Data obtained from 1996-2006 were analysed. At baseline, there were 804 patients with Type 2 diabetes mellitus (mean age 60 years) and 2983 patients without. Incident CVD (n = 458) was defined as hospital-verified myocardial infarction, stroke, vascular death and the composite of these vascular events. Both Type 2 diabetes [hazard ratio (HR) 1.42, 95% confidence interval (CI) 1.16, 1.75] and microalbuminuria (HR 1.86, 95% CI 1.49, 2.33) increased the risk of new cardiovascular events in univariate analyses. From multivariable models, presence of diabetes remained significantly and independently related to incident CVD (HR 1.42, 95% CI 1.11, 1.80)....Continue Reading
References
Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Apr 1, 1995·Diabetes·M P Stern
Feb 1, 1993·Diabetes Care·J StamlerD Wentworth
Jul 14, 1997·Archives of Internal Medicine·S F Dinneen, H C Gerstein
Jul 15, 1997·The American Journal of Cardiology·S AgewallB Fagerberg
Mar 14, 1998·Diabetologia·P FiorettoR Nosadini
Aug 14, 1998·Diabetes Care·B V HowardE T Lee
Oct 29, 1998·Diabetes·M B MattockP G Jackson
Aug 14, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·K Borch-JohnsenJ S Jensen
Dec 23, 1999·European Journal of Epidemiology·P C SimonsY van der Graaf
May 2, 2000·Archives of Internal Medicine·C T ValmadridB E Klein
Feb 15, 2001·Archives of Internal Medicine·P A LotufoJ E Manson
Jul 31, 2001·JAMA : the Journal of the American Medical Association·H C GersteinUNKNOWN HOPE Study Investigators
Aug 4, 2001·Archives of Internal Medicine·F B HuJ E Manson
Aug 21, 2001·Journal of Insurance Medicine·K Petersen
Sep 13, 2002·Journal of the American College of Cardiology·Eunyoung ChoFrank B Hu
Mar 13, 2003·Kidney International·Guruprasad ManjunathMark J Sarnak
Aug 12, 2003·European Heart Journal·Annemarie BeckerCoen D A Stehouwer
Apr 13, 2004·International Journal of Epidemiology·Matthew F YuyunUNKNOWN European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study
Apr 22, 2004·Journal of the American Society of Nephrology : JASN·Daniel E WeinerMark J Sarnak
Jun 24, 2004·Circulation·Klaus KlausenJan Skov Jensen
Oct 16, 2004·Kidney International. Supplement·Coen D A StehouwerLex M Bouter
Apr 12, 2005·Current Opinion in Nephrology and Hypertension·Matthew F YuyunNicholas J Wareham
Jul 22, 2005·Clinical Science·Casper G Schalkwijk, Coen D A Stehouwer
Dec 21, 2005·Diabetologia·A JuutilainenM Laakso
Apr 14, 2006·European Heart Journal·Christa MeisingerUNKNOWN KORA Study Group
Jul 11, 2006·Journal of the American Society of Nephrology : JASN·Coen D A Stehouwer, Yvo M Smulders
Citations
Oct 20, 2011·The Tohoku Journal of Experimental Medicine·Kyoko YamamotoKatsumi Yoshida
Feb 9, 2012·International Journal of Pediatrics·Allison B DartHeather J Dean
Jan 11, 2013·European Journal of Clinical Investigation·Sharmini SelvarajahUNKNOWN SMART study group
Mar 12, 2010·Diabetes/metabolism Research and Reviews·Agnès MathesonBradley J Walsh
Nov 17, 2009·Internal Medicine·Tayyibe SalerMustafa Yenigun
Dec 18, 2010·Magyar onkologia·György LosonczyJudit Moldvay
Feb 6, 2014·PloS One·Kyoko AokiYoshihiko Tsumura
Feb 23, 2020·International Journal of Molecular Sciences·Xiaoping CaiPaul K Witting
Mar 23, 2019·Frontiers in Immunology·Belal ChamiPaul K Witting